Table of Contents
Executive Summary
- Key Trends in the Neurodegenerative Disease Market
- Methodology and Definitions
Alzheimer' s Disease
- Acetylcholinesterase Inhibitors
- Aricept (donepezil)
- Exelon (rivastigmine tartrate
- Razadyne (galantamine)
- NMDA Antagonists
- Namenda (memantine HCI)
- Ebixa (memantine HCI)
- Amyloid Beta Therapies
- Bapineuzumab (AAB-001)
- Ly450139
- LY2062430
- ACC-001
- Other Alzheimer' s Therapies
- Abilify (aripiprazole)
- Dimebon (dimebolin)
- AZD3480/TC-1734 (ispronicline)
- SB-742457
- Tanakan (EGb751, standardized ginkgo biloba)
- Avandia XR (extended-release rosiglitazone)
- MEM 1003
Multiple Sclerosis
- Interferon Betas
- Avonex (interferon beta-1a)
- Rebif (interferon beta-1a)
- Betaseron (interferon beta-1b)
- Immunomodulators
- Copaxone (glatiramer acetate)
- Fingolimod/FTY720
- BG-12/Oral Fumarate
- Laquinimod
- Oral Leustatin (cladribine)
- Teriflunomide/HMR 176
- Monoclonal Antibodies
- HuMax-CD20 (ofatumumab)
- Campath (alemtuzumab)
- Rituxan/Mabthera (rituximab)
- Tysabri/Antegren (natalizumab)
- Firategrast/SB683699
- Other Therapies
- Fampridine-SR (4-aminopyridine)
- Dirucotide/MBP 8298
Parkinson' s Disease
- Dopaminergic Drugs
- Comtan (entacapone)/Stalevo (combination)
- Mirapex (pramipexole)
- Sinemet (carbidopa + levodopa)
- Apokyn (apomorphine)
- Requip XL (ropinirole)
- Other Therapies
- Azilect/Agilect (rasagiline)
- ACP-103 (pimavanserin tartrate)
- Droxidopa
CHARTS AND GRAPHICS
Executive Summary
- Figure E.1: Total Sales for Neurodegenerative Indications, 2004-2012 (in
billions)
- Figure E.2: Total sales for Alzheimer' s Disease by Drug Class, 2006-2012
(in millions)
- Figure E.3: Top-Selling Alzheimer' s Drugs
- Figure E.4: Total Sales for Multiple Sclerosis by Drug Class, 2004-2012
(in millions)
- Figure E.5: Top-Selling Multiple Sclerosis Drugs
- Figure E.6: Total Sales for Parkinson' s by drug class, 2005-2012 (in
millions)
- Figure E.7: Top-Selling Parkinson' s Drugs
Alzheimer' s Disease
- Profiled Alzheimer' s Drugs
- Profiled Alzheimer' s Drugs, Continued
- Alzheimer' s Drug Sales: 2004-2012, In Billions
Acetylcholinesterase Inhibitors
- Profiled AChEl Inhibitors
- AChEl Sales: 2004-2012, in Millions
- Aricept (donepezil)
- Aricept Materiality to Eisai: 2007
- Aricept Materiality to Pfizer: 2007
- Aricept Sales: 2004-2012
- Exelon (rivastigmine tartrate)
- Exelon Materiality: 2007
- Exelon Materiality: 2012
- Exelon Sales: 2004-2015
- Razadyne (galantamine)
- Razadyne Materiality: 2007
- Razadyne Materiality: 2012
- Razadyne Sales: 2004-2012
NWDA Antagonists
- Profiled NMDA Antagonists
- NMDA Antagonist Sales: 2004-2012, in Millions
- Namenda (memantine HCI)
- Namenda Materiality: 2007
- Namenda Materiality: 2012
- Namenda Sales: 2004-2013
- Ebixa (memantine HCI)
- Ebixa Materiality: 2007
- Ebixa Materiality: 2012
- Ebixa Sales: 2004-2012
Amyloid Beta Therapies
- Profiled Drugs Targeting Amyloid Beta
- Amyloid Beta Drug Sales: 2004-2012, in Millions
- Bapineuzumab (AAB-001)
- Bapineuzumab Materiality: 2011
- Bapineuzumab Materiality: 2012
- Bapineuzumab Sales: 2011-2015
- LY450139
- LY450139 Materiality: 2012
- LY450139 Sales: 2012-2015
- LY2062430
- LY2062430 Materiality: 2012
- LY2062430 Sales: 2012-2015
- ACC-001
- ACC-001 Materiality: 2012
- ACC-001 Sales: 2012-2015
Other Therapies
- Profiled Alzheimer' s Drugs Targeting Other Neurotransmitters
- Other Profiled Alzheimer' s Drugs
- Alzheimer' s Neurotransmitter Sales, Excluding Ability: 2011-2015, in
Millions
- Other Alzheimer' s Drug Sales: 2005-2015, in Millions
- Abilify (aripiprazole)
- Abilify Materiality: 2007
- Abilify Materiality: 2012
- Abilify Sales: 2004-2014
- Dimebon (dimebolin)
- Dimebon Materiality to Pfizer: 2010
- Dimebon Materiality to Medivation: 2010
- Dimebon Materiality to Pfizer: 2012
- Dimebon Materiality to Medivation: 2012
- Dimebon Sales: 2011-2015
- AZD3480/TC-1734 (ispronicline)
- AZD3480 Materiality: 2011
- AZD3480 Materiality: 2012
- AZDE3480 Sales: 2012-2014
- SB-742457
- SB-742457 Materiality: 2012
- SB-742457 Sales: 2012-2015
- Tanakan (EGb751, standardized ginkgo biloba)
- Tanakan Materiality: 2007
- Tanakan materiality: 2012
- Tanakan Sales: 2012-2015
- Avandia XR (extended-release rosiglitazone)
- Avandia XR Materiality: 2012
- Avandia XR Sales: 2012-2015
- MEM 1003
Multiple Sclerosis
- Profiled Multiple Sclerosis Drugs
- Profiled Monoclonal Antibodies for Multiple Sclerosis
- Profiled Multiple Sclerosis Drugs, Continued
- Multiple Sclerosis Drug Sales: 2006-2012, in Billions
Interferon Betas
- Profiled Interferons
- Interferon Sales: 2006-2013, in Millions
- Avonex (interferon beta-1a)
- Avonex Materiality: 2007
- Avonex Materiality: 2012
- Avonex Sales: 2004-2013
- Rebif (interferon beta-1a)
- Rebif Materiality: 2007
- Rebif Materiality: 2012
- Rebif Sales: 2000-2013
- Betaseron (interferon beta-1b)
- Betaseron Materiality: 2007
- Betaseron Materiality: 2012
- Betaseron Sales: 2005-2014
- Immunomodulators
- Profiled Immunomodulators
- Immunomodulator Sales: 2006-2012, in Millions
- Copaxone (glatiramer acetate)
- Copaxone Materiality: 2007
- Copaxone Materiality: 2012
- Copaxone Sales: 2006-2012
- Fingolimod/FTY720
- Fingolimod Materiality: 2010
- Fingolimod Materiality: 2012
- Fingolimod Sales: 2010-2015
- BG-12/Oral Fumarate
- BG-12 Materiality: 2011
- BG-12 Materialtiy: 2012
- BG-12 Sales: 2011-2012
- Laquinimod
- Laquinimod Materiality: 2011
- Laquinimod Materiality: 2012
- Laquinimod Sales: 2011-2012
- Oral Leustatin (cladribine)
- Oral Leustatin Materiality: 2010
- Oral Leustatin Materiality: 2012
- Oral Leustatin Sales: 2010-2012
- Teriflunomide/HMR 1726
- Teriflunomide Materiality: 2013
- Teriflunomide Sales: 2013-2015
Monoclonal Antibodies
- Profiled Anti-CD20 & Anti-CD52Drugs
- Profiled VLA-4 Antibodies
- VLA-4 Antibody Sales: 2008-2012, in Millions
- HuMax-CD20 (ofatumumab)
- HuMax-CD20 Materiality: 2009
- HuMax-CD20 Materiality: 2012
- HuMax-CD20 Sales: 2009-2012
- Campath (alemtuzumab)
- Campath Materiality: 2007
- Campath Materiality: 2012
- Campath Sales: 2005-2012
- Rituxan/MabThera (rituximab)
- Materiality to Bl: 2007
- Materiality to Roche: 2007
- Materiality to Genentech: 2007
- Rituxan Sales: 2005-2015
- Tysabri/Antegren (natalizumab)
- Tysabri Materiality to Elan: 2007
- Tysabri Materiality to Biogen Idec: 2007
- Tysabri Materiality to Elan: 2012
- Tysabri Materiality to Biogen Idec: 2012
- Tysabri Sales: 2005-2012
- Firategrast/SB683699
- Firategrast Materiality: 2012
- Firategrast Sales: 2012-2015
Other Therapies
- Other Profiled MS Drugs
- Other MS Sales: 2009-2013, in Millions
- Fampridine-SR (4-aminopyridine)
- Materiality to Acorda: 2009
- Materiality to Elan: 2009
- Materiality to Acorda: 2012
- Materiality to Elan: 2012
- Fampridine-SR Sales: 2009-2013
- Dirucotide/MBP 8298
- Dirucotide Materiality: 2011
- Dirucotide Materiality: 2012
- Dirucotide Sales: 2011-2015
Parkinson' s Disease
- Profiled Parkinson' s Drugs
- Parkinson' s Drug Sales: 2005-2012, in Billions
Dopaminergic Drugs
- Profiled Dopaminergic Parkinson' s Drugs
- Dopaminergic Drug Sales: 2004-2012, in Millions
- Comtan (entacapone)/ Stalevo (combination)
- Comtan+Stalevo Materiality: 2007
- Comtan+Stalevo Materiality: 2012
- Somtan+Stalevo Sales: 2005-2015
- Mirapex (pramipexole)
- Mirapex Materiality: 2007
- Mirapex Materiality: 2011
- Mirapex Sales: 2005-2011
- Sinemet (caribidopa + levodopa)
- Sinemet Materiality: 2007
- Sinemet Materialtiy: 2012
- Sinemet Sales: 2007-2015
- Apokyn (apomorphine)
- Apokyn Materiality: 2007
- Apokyn Materiality: 2012
- Apokyn Sales: 2005-2012
- Requip XL (ropinirole)
- Requip XL Materiality: 2009
- Requip XL Materiality: 2009
- Requip XL Sales: 2009-2012
Other Therapies
- Other Profied Parkinson' s Drugs
- Other Parkinson' s Drug Sales: 2006-2012, in Millions
- Azilect/Agilect (rasagiline)
- Azilect Materiality: 2007
- Azilect Materiality: 2012
- Azilect Sales: 2006-2012
- ACP-103 (pimavanserin tartrate)
- ACP-103 Materiality: 2009
- ACP-103 Materiality: 2012
- ACP-103 Sales: 2009-2015
- Droxidopa
- Droxidopa Materiality: 2010
- Droxidopa Materiality: 2012
- Droxidopa Sales: 2010-2013
|
Related Report
|
View Cart
